相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study
Adrian Campos et al.
PHARMACOGENOMICS JOURNAL (2022)
Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study
Marco Calabro et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)
Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders
Julia Sagahon-Azua et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2021)
Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure A Systematic Review and Meta-analysis
Filip Milosavljevic et al.
JAMA PSYCHIATRY (2021)
CYP2C19 polymorphisms are associated with severity of depression at initial evaluation and after the treatment independently of the prescribed medications: 4 weeks prospective study
Robertas Strumila et al.
PSYCHIATRIC GENETICS (2021)
Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients
Line S. Braten et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements
Rawan Shekhani et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Theo Vos et al.
LANCET (2020)
Patients with major depressive disorder have lower cerebral serotonin 4 receptor binding than healthy controls
K. Koehler-Forsberg et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2020)
CYP2C19 genotype, physician prescribing pattern, and risk for long QT on serotonin selective reuptake inhibitors
Natasha Petry et al.
PHARMACOGENOMICS (2019)
Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients
Marin M. Jukic et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies
Chiara Fabbri et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2018)
Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
Adela Taranu et al.
PHARMACOGENOMICS (2017)
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects
Y. Zhou et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials
Yu Hayasaka et al.
JOURNAL OF AFFECTIVE DISORDERS (2015)
Exploring the role of drug-metabolising enzymes in antidepressant side effects
Karen Hodgson et al.
PSYCHOPHARMACOLOGY (2015)
Genetic differences in cytochrome P450 enzymes and antidepressant treatment response
Karen Hodgson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation
Yingying Kumar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
PREDICTIVE SOCIOECONOMIC AND CLINICAL PROFILES OF ANTIDEPRESSANT RESPONSE AND REMISSION
Felipe A. Jain et al.
DEPRESSION AND ANXIETY (2013)
Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression
Chee Ng et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2013)
What does the HAMD mean?
Stefan Leucht et al.
JOURNAL OF AFFECTIVE DISORDERS (2013)
COMPREHENSIVE REVIEW OF FACTORS IMPLICATED IN THE HETEROGENEITY OF RESPONSE IN DEPRESSION
Gebra Cuyun Carter et al.
DEPRESSION AND ANXIETY (2012)
Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response
Ming-Hsien Tsai et al.
PHARMACOGENOMICS (2010)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Sex differences in antidepressant response in recent antidepressant clinical trials
A Khan et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Amitriptyline or not, that is the question:: Pharmacogenetic testing of CYP2D6 and CYP219 identifies patients with low or high risk for side effects in amitriptyline therapy
W Steimer et al.
CLINICAL CHEMISTRY (2005)
Predictors of antidepressant response: A selective review
S Dodd et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2004)
Antidepressant side effects in depression patients treated in a naturalistic setting: A study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine
JD Vanderkooy et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2002)
分享论文
